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derived factor (PEDF) demonstrated a potency to control
choroidal neovascularization in age-related macular degener-
ation (AMD) patients. The goal of the present study was the
development of an efficient and safe technique to integrate,
ex vivo, the PEDF gene into retinal pigment epithelial
(RPE) cells for later transplantation to the subretinal space
of AMD patients to allow continuous PEDF secretion in the
vicinity of the affected macula. Because successful gene ther-
apy approaches require efficient gene delivery and stable
gene expression, we used the antibiotic-free pFAR4 mini-
plasmid vector to deliver the hyperactive Sleeping Beauty
transposon system, which mediates transgene integration
into the genome of host cells. In an initial study, lipofec-
tion-mediated co-transfection of HeLa cells with the SB100X
transposase gene and a reporter marker delivered by pFAR4
showed a 2-fold higher level of genetically modified cells
than when using the pT2 vectors. Similarly, with the pFAR4
constructs, electroporation-mediated transfection of primary
human RPE cells led to 2.4-fold higher secretion of recombi-
nant PEDF protein, which was still maintained 8 months after
transfection. Thus, our results show that the pFAR4 plasmid
is a superior vector for the delivery and integration of trans-
genes into eukaryotic cells.
INTRODUCTION
Since the first attempts to treat genetically based diseases using
retroviral vectors to deliver transgenes to host cells,1,2 various
non-viral vectors and transgene delivery methods have been devel-
oped, including nanoparticle-mediated gene delivery,3 physical
methods,4–6 plasmids,7–9 and DNA transposons, which are DNA se-
quences that can move from one location and become integrated
into another locus of the genome.10 Even though transposons
were discovered in the 1950s, it has been shown only recently
that the transposon named Sleeping Beauty (SB), and especially itsMolecular
This is an open access article under the CC BY-NChyperactive form (SB100X), is able to efficiently and safely integrate
transgenes into the host genome, providing sustained transgene
expression in quiescent and dividing cells.11,12
Non-virus-mediated gene delivery often uses plasmid vectors that
usually include an antibiotic resistance marker for efficient plasmid
manufacturing. However, antibiotic resistance genes present several
safety concerns, such as the risk for horizontal gene transfer, which
could provide pathogenic bacteria with resistance to antibiotics that
are used to treat humans, and risk to patients with severe hypersen-
sitivity to antibiotics.13 In addition, because cell transfection effi-
ciency is inversely correlated with plasmid size,14–16 several research
groups have designed vectors as small as possible and devoid of
antibiotic resistance markers8,17–25 to increase both transfection ef-
ficiency and safety. To produce a small plasmid free of antibiotic
resistance marker (pFAR),26 we introduced an amber mutation
into the thyA gene of Escherichia coli, resulting in a bacterial strain
auxotrophic for thymidine and synthesized de novo a small plasmid
(pFAR4) to remove redundant sequences and introduce a suppres-
sor tRNA sequence (the selection marker) expressed from prokary-
otic regulatory sequences.26 Introduction of pFAR4 mini-plasmid
constructs into the E. coli strain auxotrophic for thymidine sup-
presses the nonsense mutation, restoring prototrophic growth to
the thyA mutant and allowing efficient plasmid production. The
reduced size of the pFAR4 vector leads to efficient transfection
and expression of transgenes in various tissues, including mouse
muscle, skin, and liver as well as transplanted tumor cells.26,27 ToTherapy: Nucleic Acids Vol. 11 June 2018 ª 2018 The Authors. 57
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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dividing cells, we combined the pFAR4 vector with the hyperactive
SB transposon system.
SB is a DNA transposon that belongs to the Tc1/mariner superfam-
ily.28 It is derived from fish transposon sequences that were subjected
to site-directed replacements and high-throughput genetic screenings
to first “awaken” and subsequently increase its mobility.28,29 The re-
sulting hyperactive transposase variant, SB100X, is an effective genetic
tool for the transposition of any eukaryotic gene flanked by inverted
terminal repeats (ITRs).30,31 The SB100X transposase binds to the
ITRs (227 bp) and catalyzes transgene transposition from a donor
plasmid into the host cells’ genome via a “cut and paste” mecha-
nism.11,12 The SB100X transposon system displays a nearly random
transgene integration profile and does not have preferences for tran-
scriptionally active regions, exhibiting lower genotoxicity than most
viral integrative vectors.31–35
The objectives of combining the pFAR4 vector with the SB100X trans-
poson system were to optimize essential parameters; i.e., efficiency of
transfection, transgene expression level in dividing cells (such as
HeLa cells), and somatic differentiated cells (such as retinal pigment
epithelial [RPE] cells). Our particular interest in RPE cells stems from
our objective to develop a gene therapeutic treatment for neovascular
age-related macular degeneration (AMD).
AMD is the most common cause of severe vision loss in patients over
the age of 60 and the major cause of blindness in industrialized coun-
tries.36–38 There are two distinct types of AMD: a slowly progressing
dry (atrophic) form and a rapidly developing wet (neovascular) form,
in which choroidal blood vessels grow through Bruch’s membrane
into the subretinal space. The symptoms are characterized by the
degeneration of RPE cells, alterations in Bruch’s membrane, neural
retinal ganglion cell degradation, and the death of photoreceptor cells.
Neovascular AMD (nvAMD) is the result of an imbalance between
the retinal anti-angiogenic pigment epithelium-derived factor
(PEDF) and the pro-angiogenic vascular endothelial growth factor
(VEGF). In pathological states, decreased production of PEDF
and/or increased VEGF levels will result in choroidal neovasculari-
zation (CNV).39,40 Current treatments for nvAMD are based on re-
establishment of the balance between the PEDF and VEGF proteins,
mostly by using biopharmaceuticals that inhibit VEGF, allowing
CNV control in 90% of patients and significant vision improvement
in 30%–40% of treated patients.41,42 Effectiveness in responsive pa-
tients requires, however, frequent, often monthly, intravitreal injec-
tions of short half-life anti-VEGFs, which have been linked to local
side effects, such as endophthalmitis, ocular hypertension,43 sub-
macular hemorrhage,44 and rarely occurring thromboembolic
events.45 To reduce treatment costs and avoid side effects, an alter-
native approach for CNV inhibition includes increasing PEDF
levels, the natural antagonist of VEGF, by PEDF gene delivery to
the retina of AMD patients. Using adenoviral gene vectors, Campo-
chiaro et al.46,47 reported a significant improvement in 25% of pa-58 Molecular Therapy: Nucleic Acids Vol. 11 June 2018tients but no further follow-up. Our therapeutic approach comprises
the subretinal transplantation of genetically modified autologous
pigment epithelial cells that continuously secrete the PEDF protein
for the life of AMD patients. Initial studies performed using conven-
tional plasmids allowed demonstration, both in vitro and in animal
models, of the feasibility of the proposed treatment.48–50 To imple-
ment clinical trials, further improvements are nevertheless required,
such as removal of antibiotic resistance markers from the gene
vectors.
In this study, we compared pFAR4 constructs and conventional plas-
mids paired with the SB100X transposon system for transfection effi-
ciency, transposon integration, and transgene expression levels in
easy-to-transfect HeLa cells as well as in primary human RPE cells.
Here we report that the pFAR4 mini-plasmids mediate higher cell
transfection efficiency, superior PEDF expression levels, and sus-
tained, long-term PEDF secretion by RPE cells.
RESULTS
pFAR4 Promotes Higher Transgene Integration Efficiency in
HeLa Cells Compared with pT2
The suitability of delivering, integrating, and expressing a transgene
in a host cell was preliminary investigated in HeLa cells transfected
with a plasmid carrying the transposon and another encoding the
SB100X transposase. The transfection and transposition efficiencies
were assessed using a colony-forming assay based on the quantifica-
tion of clones containing the inserted transgene. For this purpose, the
neomycin resistance gene expressed from the simian virus 40 (SV40)
promoter and carried by the pT2/SV-Neo transposon plasmid51 was
subcloned into the pFAR4 mini-plasmid, resulting in the pFAR4-
ITRs-SV-Neo construct (Figure 1A). Similarly, the hyperactive
SB100X transposase expressed from the human cytomegalovirus
(CMV) promoter carried by pCMV-CAT(T7)-SB100X29 was intro-
duced into the pFAR4 mini-plasmid, leading to the pFAR4-CMV-
SB100X construct. Thus, the original and the antibiotic-free plasmids
contain identical eukaryotic expression cassettes but alternative
plasmid backbones (Figure 1A), resulting in a decrease in plasmid
size of 35%.
To assess whether the decrease in plasmid size affects the number of
transgenic colonies, HeLa cells were co-transfected with either 500 or
50 ng of pT2/SV-Neo combined with 50 or 5 ng of pCMV-CAT(T7)-
SB100X, respectively, or with 328.3 or 32.8 ng of pFAR4-ITRs-SV-
Neo combined with 32.5 or 3.3 ng of pFAR4-CMV-SB100X, respec-
tively (Figure 1B). A transposase-to-transposon ratio of 1:10 was
chosen to avoid the “overproduction inhibition” (OPI) effect that
negatively affects SB transposition efficiency in the presence of high
transposase levels.52–54 With higher plasmid amounts, a higher num-
ber of neomycin-resistant colonies (1.6-fold, p < 0.0001) was
obtained when the pFAR4 mini-plasmid was used compared with
the pT2 regular plasmid. The effect was even more pronounced,
1.8-fold enhancement (p < 0.005), when HeLa cells were transfected
with a lower plasmid amount (Figure 1B). In the absence of the
SB100X transposase, negligible numbers of neomycin-resistant
Figure 1. Delivery of the Sleeping Beauty
Transposon System by the pFAR4 Vector Mediates
a Higher Number of Neomycin-Resistant Clones
HeLa cells were co-transfected with either pT2/SV-Neo
and pCMV-(CAT)T7-SB100X (ratio transposon plasmid:
transposase plasmid = 500:50 ng or 50:5 ng) or an
equimolar amount of pFAR4-ITRs-SV-Neo and pFAR4-
CMV-SB100X (ratio transposon plasmid:transposase
plasmid = 328.3:32.5 ng or 32.8:3.3 ng). The total DNA
amount was adjusted to 550 ng using pFAR4 empty
vector. (A) Both vectors contain identical eukaryotic
expression cassettes but alternative plasmid backbones,
differing by their size and the selection markers used for
their propagation in E. coli. (B) Transgenic rates are the
mean number of NeoR colonies after 11 days of growth in
selection medium per number of cells seeded ± SD. Data
are the average of three independent transfection exper-
iments with replicated cell seedings (n = 23) for the “high”
plasmid amount and four independent transfection ex-
periments for the “low” plasmid amount (n = 40). +SB
and SB indicate the presence or absence of the trans-
posase plasmid, respectively. **p < 0.005, ***p < 0.0001,
using an unpaired two-tailed t test.
www.moleculartherapy.orgcolonies were obtained, indicating that the higher number of colonies
obtained with the pFAR4 vector resulted from transposition events
catalyzed by the SB100X transposase.
Because the pFAR4 constructs are significantly smaller than the con-
ventional plasmids, we next investigated the effect of the size of the
transposon plasmid on transposition rates by using pFAR4 as the
only SB100X delivery vector. Thus, HeLa cells were co-transfected
with 5 ng of pFAR4 encoding SB100X and either 50 ng of pFAR4-
ITRs-SV-Neo or an equimolar amount of pT2/SV-Neo (76.1 ng).
As observed previously, a higher number of neomycin-resistant col-
onies (a 2-fold increase; p < 0.0001) was obtained when the neoR
transgene was delivered by pFAR4 compared with the pT2 control
plasmid (Figure 2A). These results suggest that the higher number
of neomycin-resistant colonies obtained with the pFAR4 constructs
is mediated by the smaller size of the pFAR4 transposon mini-
plasmid.
Following the enumeration of colonies after 11 days of selection,
neomycin-resistant colonies were propagated in antibiotic-contain-
ing medium, and the transposon copy number was determined by
qPCR using primers specific to the neomycin resistance gene (Fig-
ure 2B). An average of 6.0 ± 1.4 copies (n = 12 clones analyzed)
were integrated in the genome of HeLa cells transfected with
the neoR gene carried by pFAR4 (pFAR4-ITRs-SV-Neo), whereas
4.5 ± 1.2 copies (n = 9 clones analyzed) were quantified when HeLa
cells were transfected with the neoR gene delivered by the pT2
plasmid (pT2/SV-Neo). The statistical analysis of transgene copyMolecularnumber quantified in cells transfected with
either pFAR4-ITRs-SV-Neo or pT2/SV-Neo re-
vealed that the difference is not significant.Thus, the pFAR4 plasmid appears to promote a higher number of
transgenic cells without increasing the number of transgene copies in-
tegrated per cell.
pFAR4 Promotes a Higher Number of Transgenic Cells under
Non-selective Conditions
Because one of our goals is to take the pFAR4 mini-plasmid merged
with the SB100X transposon system to the clinic, our next step was to
assess the combination of both molecular tools in the absence of se-
lection pressure for integration events. For this purpose, the
neomycin resistance gene was substituted with a reporter gene encod-
ing Venus, a yellow fluorescent protein, expressed from the SV40 pro-
moter, resulting in two constructs, pFAR4-ITRs-SV-Venus (2,984 bp)
and pT2/SV-Venus (4,878 bp). These two plasmid constructs allow
assessment of the effect of plasmid size at two main time points re-
flecting the transfection and transposition events. For this study,
HeLa cells were transfected with either pFAR4-ITRs-SV-Venus
(300 or 50 ng) or an equimolar amount of pT2/SV-Venus (490 or
82 ng) in the presence or absence of transposase. Two days after
transfection, in the presence of 10-fold less pFAR4-CMV-SB100X
(30 or 5 ng), a higher percentage of fluorescent cells was observed
when the cells were transfected with pFAR4-ITRs-SV-Venus
(80.6% for 300 ng and 55.6% for 50 ng) than with an equimolar
amount of pT2/SV-Venus (60.6% for 490 ng and 37.4% for 82 ng).
Similarly, in the absence of transposase, the percentage of fluorescent
cells dropped from 83.2% when the cells were transfected with 300 ng
of pFAR4-ITRs-SV-Venus to 63.6% when using 490 ng of pT2/SV-
Venus. When the cells were transfected with either 50 ng ofTherapy: Nucleic Acids Vol. 11 June 2018 59
Figure 2. Delivery of the Sleeping Beauty
Transposon by pFAR4 Promotes a Higher Number
of NeoR Clones
HeLa cells were co-transfected with an equimolar amount
of transposon plasmid (pT2/SV-Neo, 76.1 ng; pFAR4-
ITRs-SV-Neo, 50 ng) either in the absence (SB) or
presence (+SB) of transposase (5 ng of pFAR4 encoding
SB100X). The DNA amount was adjusted to 500 ng using
empty pFAR4 plasmid. (A) Eleven days after transfection,
NeoR colonies were enumerated. Data represent the
mean number of NeoR colonies per number of seeded
cells for three independent experiments ± SD; experi-
ments were performed in quadruplicates with various
number of cells seeded (n = 40). ***p < 0.0001, using an
unpaired two-tailed t test. (B) The number of transposon
integration events was determined by qPCR (performed
twice in triplicate) and normalized to the RPPH1 gene
using genomic DNA prepared from 9 and 12 NeoR clones
selected from the three independent transfections of HeLa cells with the pT2 and pFAR4 transposon constructs, respectively. The number of integrated neoR gene copies
varied among clones, but the mean (± SD) did not differ statistically with the type of gene vector used (ns, not significantly different, using Mann-Whitney test).
Molecular Therapy: Nucleic AcidspFAR4-ITRs-SV-Venus or 82 ng of pT2/SV-Venus, the percentage of
fluorescent cells dropped from 62.3% to 43.1% (Figure 3A). Thus, the
difference in size between the pFAR4 and pT2 gene vectors has pri-
marily an effect on transfection efficiency.
To assess the effect of plasmid size on transgene integration, trans-
fected cells were then propagated for 3 weeks, and fluorescent cells
were analyzed by flow cytometry. For both plasmid amounts and in
the presence of transposase encoded by pFAR4, the percentage of
fluorescent cells varied between 20% and 23% for cells transfected
with pT2/SV-Venus and between 27% and 28% for cells transfected
with pFAR4-ITRs-SV-Venus. In the absence of the SB100X transpo-
sase, the percentage of fluorescent cells was, for all conditions tested,
less than 1.3%. When cells were transfected with the Venus gene
carried by the pFAR4 plasmid, the number of fluorescent cells
was 1.2-fold greater with low and 1.4-fold greater with a high
plasmid amount than when the cells were transfected with the
pT2/SV-Venus plasmid (Figure 3B). In this latter case, the differ-
ence between both plasmid constructs was statistically significant,
with p < 0.01.
Thus, under either selective (such as in the presence of antibiotics) or
non-selective conditions for transgenic cells, pFAR4 is an efficient
vector for the delivery of the SB100X transposon system and the inte-
gration of transgenes into the host cell’s genome, a useful feature for
the transfection of primary cells or cells sensitive to a high amount of
plasmid DNA.
Primary Human RPE Cells a Secrete Higher PEDF Level When
Transfected with pFAR4 Constructs
To determine whether the pFAR4 plasmid is an effective vector for
the delivery of transgenes to primary somatic cells, we investigated
the transfection of RPE cells, which we plan to use as a means to
deliver therapeutic molecules to the subretinal space of patients
suffering from neovascular AMD. In these experiments, electropora-60 Molecular Therapy: Nucleic Acids Vol. 11 June 2018tion was used to deliver the plasmids to the cells because lipofection of
primary pigment epithelial cells has been shown to be poor.55 In all
experiments with RPE cells, SB100X was encoded by the pFAR4
plasmid, and a transposase to transposon ratio of 1 to 16 was used.
13 days after transfection, human RPE cells isolated from 4 donor
eyes and transfected with SB100X and the Venus gene carried by
the pFAR4 plasmid showed an average of a 2.2-fold greater number
of fluorescent cells compared with cells transfected with the transpo-
sase gene and the Venus gene encoded by pT2 (p < 0.03). However,
the mean fluorescence intensity was similar, indicating that the
pFAR4 vector mostly promoted a higher transfection rate
(Figure 4A).
PEDF secretion by human RPE cells isolated from 10 donor eyes and
transfected with SB100X and the human PEDF gene expressed from
the CMV promoter and carried by either a pT2 or pFAR4 plasmid
was next analyzed by western blot. Three weeks after transfection,
RPE cells transfected with pFAR4-PEDF showed an average 100% in-
crease in secreted PEDF (p% 0.001) compared with cells electropo-
rated in the absence of any plasmid, whereas cells transfected with
pT2-PEDF showed only an average 50% increase (p % 0.001) (Fig-
ure 4B). Three weeks after transfection, PEDF expression was
analyzed by quantitative PCR in human RPE cells isolated from
seven donor eyes. Compared with endogenous PEDF expression, a
significant increase in total (endogenous plus recombinant) PEDF
expression was observed, regardless of whether the cells had been
transfected with the pFAR4-PEDF or pT2-PEDF plasmids (data not
shown). Notably, total PEDF expression was 1.9-fold higher in cells
transfected with pFAR4-PEDF than in cells transfected with the
PEDF gene carried by pT2 (p < 0.05) (Figure 4C). Finally, secreted
PEDF was quantified by ELISA in medium of RPE cells isolated
from nine human donor eyes. Three weeks after transfection,
cells transfected with pFAR4-PEDF secreted 0.84 ± 1.14 ng of
PEDF/hr/104 cells, whereas cells transfected with pT2-PEDF
secreted 0.35 ± 0.47 ng of PEDF/hr/104cells. The culture medium
Figure 3. Comparative Analysis of Transfection
Efficiency and Transgenic Rate Using the pFAR4 or
the pT2 Plasmid to Encode the Venus Gene
HeLa cells were co-transfected with either a high or a low
plasmid amount using the following constructs: pFAR4-
ITRs-SV-Venus (2,984 bp, 300 or 50 ng) or an equimolar
amount of pT2/SV-Venus (4,878 bp, 490 or 82 ng) either
without (SB) or plus SB100X transposase encoded by
the pFAR4 plasmid (30 or 5 ng). Using the pGL3 empty
vector, the total amount of plasmid was adjusted to 800 or
500 ng for the high or low conditions, respectively. (A) Data
represent the mean number of fluorescent cells ± SD,
obtained 2 days after six and four independent trans-
fections for the high and low plasmid amounts, respec-
tively. **p < 0.01, *p < 0.05; ns, not statistically different
using Mann-Whitney test. (B) To assess transgenic rates,
2 days after transfection, 104 cells were seeded in plates,
and the percentage of fluorescent cells was determined by fluorescence-activated cell sorting (FACS) after 5 passages. The transgenic rate in cells transfected with pFAR4-
ITRs-SV-Venus was related to that obtained with pT2/SV-Venus, which was set to 1 (±SD). **p < 0.01; ns, not statistically different usingWilcoxon signed-rank test; n = 5 or 3
for the high or low plasmid amount conditions, respectively.
www.moleculartherapy.orgof non-transfected cells contained 0.07 ± 0.06 ng of PEDF/hr/104cells
(Figure 4D). Thus, transfection of human RPE cells with a pFAR4 en-
coding PEDF leads to a significant increase in PEDF expression, al-
lowing for a 2.4-fold higher secreted PEDF level than that obtained
with pT2-PEDF (p % 0.05) and a 12-fold increase compared with
non-transfected control cells (p% 0.001).
Long-term secretion of PEDF by RPE cells was analyzed by immuno-
blotting for a period of 8 months. PEDF secretion, measured as mean
normalized signal intensity, for pT2-PEDF-transfected cells was
reduced by 27.8% from 51 to 240 days, whereas, for cells transfected
with an equimolar amount of the pFAR4-PEDF plasmid, PEDF secre-
tion increased by 42% (Figure 5A; Table S1). Comparison of secreted
PEDF levels by RPE cells transfected with either the pFAR4-PEDF or
the pT2-PEDF transposon plasmids showed a statistically significant
difference 51 and 103 days after transfection, whereas, at later time
points (on days 150, 197, and 240), the difference was no longer sta-
tistically significant, even though—referring to the samples of every
individual RPE cell isolate—the averaged amounts secreted by the
pFAR4-PEDF-transfected cell samples were 1.2- to 5.7-fold higher
at 150 days, 1.3- to 18.1-fold higher at 197 days, and 1.2 to
26.7-fold higher at 240 days compared with the averaged amounts
secreted by the respective pT2-PEDF-transfected cell samples (Fig-
ure 5A; Table S1). Furthermore, the proportion of isolates transfected
with pFAR4-PEDF that secreted PEDF at levels superior to the high-
est level obtained with pT2-PEDF-transfected cells ranged between
25% and 40%.
Long-term PEDF gene expression was analyzed in human RPE cells
from eight donor eyes cultured for 180 ± 66 days after transfection.
For pFAR4-PEDF-transfected cells, a 2.2-fold increase in total
(endogenous plus recombinant) PEDF expression was observed
compared with the total PEDF expression in pT2-PEDF-
transfected cells (Figure 5B). This difference was statistically signifi-
cant (p = 0.0123).DISCUSSION
Successful gene therapy requires effective and safe means of modi-
fying a targeted cell or organ affected by a specific gene, whether the
gene in question is mutated, silent, or expressed at an insufficient
level. During the last two decades, several vectors have been devel-
oped to deliver genes to cells both in vivo and in vitro; however,
many delivery vectors still have limitations related to efficiency or
safety. Efficiency requires not only that the gene is successfully
introduced into the cell at therapeutic levels but also that it will ex-
press the appropriate therapeutic molecule for the necessary period
of time or for life, as may be required. Safety requires that the vector
that delivers the gene will have no effect on the host cells and that, if
it is required, the integration of the transgene into the host cell’s
genome will not disrupt the expression of other genes or prompt
the expression of genes that can cause harm to the host cell or
the organism. Here we investigated the delivery of the Venus gene
and the neomycin resistance gene in HeLa cells and of the PEDF
gene in RPE cells using the SB100X transposase to integrate the
genes into the host cell’s genome and compared the efficiency of
delivery by the pT2 and pFAR4 plasmids. Although retroviral and
lentiviral vectors and other transposons show a preference for
integration into actively transcribed genes,31,33,56 the SB transposon
displays a safe, close to random integration pattern in mammalian
genomes and is less likely to integrate into transcribed genes or
transcriptional regulatory regions.31,32 The pFAR4 mini-plasmid is
not only more effective, but it is also safer because it does not
include an antibiotic resistance gene; in fact, both the European
Medicines Agency (EMA)57 and the Food and Drug Administration
(FDA)58 advise to avoid the use of plasmids that contain antibiotic
resistance genes. In this study, it has been shown that pairing the
hyperactive SB transposon system (SB100X) and the pFAR4 vector
results in greater efficiency, as evidenced by an 2-fold increase in
neomycin-resistant HeLa cell colonies, a 2.4-fold increase in PEDF
secretion into the culture medium of cultured PEDF-transfected
primary human RPE cells, as well as higher PEDF expressionMolecular Therapy: Nucleic Acids Vol. 11 June 2018 61
Figure 4. Analysis of Transfection Efficiency, PEDF Expression, and Secretion by Primary Human RPE Cells 13 and 21 Days after Transfection
(A) Eight individual cultures of RPE cells isolated from 4 donor eyes (age, 74.0 ± 6.0 years; gender, 2 males and 2 females; time postmortem, 26.3 ± 3.9 hr; cultivation time
before transfection, 48.8 ± 10.0 days) were transfected with 30 ng pFAR4-CMV SB100X SV40 transposase and either 470 ng pT2-ITRs CAGGSVenus (0.11 pmol) or 324 ng
pFAR4-ITRs CAGGS Venus (0.11 pmol + 146 ng pFAR4/empty plasmid DNA) or without plasmid DNA as a control. Venus expression for 1 105 cells was analyzed by flow
cytometry at 13.0 ± 1.8 days after transfection. Statistical analysis using an unpaired two-tailed t test showed a significantly greater number of fluorescent cells when
transfected with pFAR4-Venus than when transfected with pT2-Venus (p = 0.0277). However, no difference in mean fluorescence intensity was noted. (B) PEDF secretion
was analyzed by western blots of culture medium of 1  104 RPE cells isolated from 10 human donor eyes (age, 68.3 ± 14.8 years; gender, 6 males and 4 females; time
postmortem, 29.5 ± 19.6 hr; cultivation time before transfection, 39.3 ± 22.3 days) and transfected with equimolar concentrations of pT2-PEDF (470 ng) or pFAR4-PEDF
(313 ng + 157 ng pFAR4/empty plasmid DNA) in the presence of 30 ng of SB100X carried by pFAR4 or without plasmid DNA as a control. Culture supernatants of 72
individual control cultures, 116 individual pT2-PEDF cultures, and 114 individual pFAR4-PEDF cultures were analyzed for total PEDF secretion 21.1 ± 1.1 days after
transfection. Loading of equal amounts of culture supernatants was proven by SDS-PAGE Coomassie G-250 staining. Using anti-PEDF antibodies, signal intensities ob-
tained with cells transfected with either pFAR4-PEDF or pT2-PEDF were normalized to the signal intensities obtained with control cells electroporated without plasmid DNA.
Total PEDF secretion from pT2-PEDF- or pFAR4-PEDF-transfected cells was significantly higher than from cells transfected without plasmid DNA (p% 0.001), and pFAR4-
PEDF-transfected cells secreted a significantly higher PEDF level than pT2-PEDF-transfected cells (p% 0.001, one-way ANOVA with Tukey’s multiple comparisons test).
(C) Relative PEDF gene expression was analyzed by qPCR for 1  104 RPE cells isolated from 7 donor eyes (age, 63.7 ± 15.5 years; gender, 5 males and 2 females; time
postmortem, 32.1 ± 23.4 hr; cultivation time before transfection, 37.6 ± 17.8 days), transfected with equimolar concentrations of pT2-PEDF and pFAR4-PEDF (using the
same conditions as described above), and cultured for 21.3 ± 1.3 days after transfection. Data for total (endogenous + recombinant) PEDF gene expression are presented as
a box and whisker plot (whiskers, minimum to maximum). Total PEDF gene expression in pFAR4-PEDF-transfected cells was related to that obtained with pT2-PEDF-
transfected cells, which was set to 1 (dashed line). The difference is statistically significant, p = 0.0406 (one sample t test), exhibiting a 1.89-fold increase. Transfection of RPE
cells with pFAR4-PEDF allowed for a significant increase in total PEDF expression (p = 0.0333, unpaired two-tailed t test) compared with the endogenousPEDF level (data not
shown). (D) Total PEDF secretion for 1  104 cells transfected with equimolar concentrations of pT2-PEDF and pFAR4-PEDF (using the same conditions as described in B)
was quantified by ELISA using RPE cells isolated from 9 human donor eyes (age, 67.4 ± 15.4 years; gender, 6 males and 3 females; time postmortem, 30.1 ± 20.7 hours;
cultivation time before transfection, 41.6 ± 22.5 days). Culture supernatants of 36 individual control cultures, 32 individual pT2-PEDF cultures, and 32 individual pFAR4-PEDF
cultures were analyzed 21.0 ± 1.1 days after transfection. Total PEDF secretion of pT2-PEDF and pFAR4-PEDF transfected cells was compared with non-transfected control
cells (p = not significant for pT2-PEDF-transfected cells and p % 0.001 for pFAR4-PEDF-transfected cells), and total PEDF secretion of pT2-PEDF-transfected cells
was compared with total PEDF secretion of pFAR4-PEDF-transfected cells (p% 0.05, one-way ANOVA with Tukey’s multiple comparisons test). All data are expressed as
mean ± SD.
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Figure 5. Analysis of Long-TermPEDF Expression and Secretion by Primary
Human RPE Cells Transfected with SB100X Encoded by pFAR4 and PEDF
Carried by Either the pFAR4 or pT2 Plasmid
(A) At the times indicated in the graph, PEDF secretion was analyzed by western
blots of culture media of 1  104 RPE cells isolated from human donor eyes
(numbers as indicated; the number of samples tested is listed in Table S1) trans-
fected with equimolar concentrations of pT2-PEDF or pFAR4-PEDF (7.50  1010
plasmid copies) combined with 30 ng of SB100X encoded by the pFAR4 plasmid.
The total plasmid amount (500 ng) was adjusted using pFAR4 empty vector. Signal
intensities obtained with pT2-PEDF-transfected and pFAR4-PEDF-transfected cells
were normalized to the signal intensities obtained with cells electroporated without
plasmid DNA. Data are presented as mean ± SD. Statistical analyses were per-
formed to compare level of PEDF secreted by cells transfected with plasmids to that
of cells electroporated without plasmid and PEDF values obtained with pFAR4-
PEDF-transfected cells versus those of pT2-PEDF cells using one-way ANOVA with
Tukey’s multiple comparisons test. *p% 0.05, **p% 0.01, ***p% 0.001. See also
Table S1. (B) Relative PEDF gene expression was analyzed by qPCR in 1 104 RPE
cells isolated from 8 human donor eyes (age, 66.3 ± 16.0 years; gender, 5 males
and 3 females; time postmortem, 31.1 ± 21.8 hr; cultivation time before transfection,
39.9 ± 23.4 days) and cultured for 180 ± 66 days after transfection with equimolar
concentrations of pT2-PEDF and pFAR4-PEDF (as described in A). Data for total
(endogenous + recombinant) PEDF gene expression are presented as a box and
whisker plot (whiskers, minimum to maximum). PEDF gene expression in pFAR4-
PEDF-transfected cells was related to that obtained with pT2-PEDF-transfected
cells, which was set to 1 (dashed line). In cells transfected with pFAR4-PEDF, the
total PEDF gene expression level was 2.2-fold higher than in cells transfected with
pT2-PEDF. This difference is statistically significant, with p = 0.0123, using one-
sample t test.
www.moleculartherapy.orgcompared with RPE cells transfected with the pT2 standard plasmid.
The increased efficiency of transfection probably results from a
faster transit of the small pFAR4-PEDF construct (3,870 bp)through the host cytoplasm to the nucleus compared with the
significantly larger pT2-PEDF construct (5,804 bp). In addition,
the smaller size of the pFAR4 constructs may favor transposon exci-
sion59 because of the shorter distance between the transposon ITRs.
Considering that less than 1%–2% of available intracellular transpo-
sons are excised from a plasmid60 (M.P. and C.M., unpublished
data), the development of molecular tools that mediate more effi-
cient transfection is an important advantage, which is particularly
relevant when a limited number of cells is available; for cells, such
as primary cells, which are difficult to transfect or when transfected
cells are sensitive to high levels of plasmid.61 Therefore, the use of
the pFAR4 plasmid paired with the SB100X transposase allows for
greater gene expression, a greater transgene product level, and,
more importantly, greater safety. Our results showing that an
average of six neoR gene copies (range, 1–15) were integrated into
the HeLa cell genome compare well with the copy number of
chimeric antigen receptor (CAR) transgenes integrated into
CD8+T cells (n = 5; range, 3–8) or CD4+T cells (n = 6; range, 3–
8) transfected with a SB transposon expressing a CD19-specific
CAR.61 Noteworthy is that the smaller size and the higher potency
of small DNA vectors (pFAR4 and minicircles) used for the SB de-
livery did not challenge the nearly close to random integration pro-
file of the SB transposon.61,62 The superior safety feature of SB,
compared with the Tol2 or piggyBac transposons, which tend to
integrate into transcription start sites or transcriptional regulatory
regions,31 promoted its translation to clinical trials.
Currently, in the United States, ten phase I clinical trials have been
launched using the SB transposon. All ten trials are based on the
genetic modification of T cells, nine for the treatment of B cell malig-
nancies and one for the treatment of metastatic breast cancer (http://
www.abedia.com/wiley/search.php). In Europe, a first-in-man clin-
ical trial pairing the pFAR4 plasmid and the SB100X transposase
is expected to be initiated in 2018 (http://www.targetAMD.eu).
Here, we have shown that delivery and integration of a transgene
are more efficient when the transgene and the transposase are en-
coded by pFAR4 plasmids. In addition, the safety and biological activ-
ity of the protocol have also been shown in animal studies.63 The
transgene expression level is not only higher using the pFAR4 and
SB100X pair, but it is also maintained over a long period of time.
Here we have shown that primary human RPE cells transfected
with the pFAR4-PEDF construct secrete sustained levels of PEDF
into the cell culture medium for the 8 months the cells were followed,
whereas only very low levels were secreted when the cells were trans-
fected using the pT2-PEDF plasmid. It is interesting to note that, dur-
ing the first 5 months, the difference between PEDF secreted by cells
transfected using pFAR4 and pT2 was statistically significant; how-
ever, by 5 months, the difference was no longer statistically significant
even though the average levels of PEDF were much higher for cells
transfected with the pFAR4 plasmid. The discrepancy could be the
result of uneven growth of the cells that were isolated from donors
of different ages (45 to 84 years), at different postmortem times
(18 to 66 hr) and of unknown/different health status. Still, the number
of isolates transfected with pFAR4-PEDF that secrete PEDF at levelsMolecular Therapy: Nucleic Acids Vol. 11 June 2018 63
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ranged between 25% and 40%.
Thus, our results show that combining the pFAR4 plasmid and the SB
transposon system for the delivery and integration of transgenes into
the genome of eukaryotic cells using either lipofection or electropora-
tion offers several advantages, such as increased transfection effi-
ciency, decreased safety concerns, sustained gene expression, and
reduced gene vector manufacturing costs compared with those of
viral vectors. The manufacturing of the pFAR4 mini-plasmid family
can be achieved in a growth medium free of thymidine and animal-
derived components (C.M., unpublished data), allowing good
manufacturing practices-compatible production, making this
plasmid family an appealing tool for cell/gene therapy clinical
applications.
MATERIALS AND METHODS
Plasmid Constructs and Manipulation
pFAR4-ITRs is a derivative of the antibiotic-free pFAR4 vector26 that
contains the ITR sequence elements extracted from pT2/BH (a gift
from P. Hackett, Addgene plasmid 26556; Cambridge MA, USA).
pFAR4-ITRs-SV-Neo (3,385 bp), pFAR4-ITRs-CAGGS-Venus
(pFAR-Venus, 4,227 bp), and pFAR4-CMV-SB100X (3,094 bp)
were constructed using standard cloning procedures and the
following donor templates: pT2/SV-Neo (5,155 bp),51 pT2-CAGGS-
Venus (pT2-Venus, 6,132 bp),29 and pCMV-CAT(T7)-SB100X
(4,752 bp).29 The pT2/SV-Venus (4,878 bp), and pFAR4-ITRs-SV-
Venus (2,984 bp) plasmids are pT2/BH and pFAR4-ITRs derivatives,
respectively. The two plasmids contain an identical eukaryotic expres-
sion cassette composed of the SV40 promoter (amplified from
pT2/SV-Neo51) and the Venus sequence (extracted from pT2-
CAGGS-Venus29). The pFAR4-ITRs-CMV-PEDF-bovine growth
hormone (BGH) (pFAR4-PEDF, 3,870 bp) and pT2/BH-CMV-
PEDF-BGH (pT2-PEDF, 5,804 bp) constructs contain a human
PEDF cDNA that was generated from ARPE-19 cells (ATCC CRL-
2302) and regulatory sequences amplified from pT2-CMV-PEDF/
EGFP.64 All pFAR4 derivatives were propagated using the dedicated
bacterial strain (TM#47-9a) genetically modified for the production
of antibiotic-free plasmids.26 All plasmids were purified using Endo-
free preparation plasmid kits (Macherey Nagel, Hoerdt, France).
Transfection of HeLa Cells
HeLa cells (ATCC, CCL-2, LGC Standards, Molsheim, France) were
cultured in minimal essential medium (MEM) supplemented with
GlutaMAX, fetal calf serum (FCS, 10%), streptomycin (100 mg/mL),
penicillin (100 U/mL), non-essential amino acids, and pyruvate
(1 mM). FCS was purchased from Sigma-Aldrich (Saint-Quentin Fal-
lavier, France), and all other reagents were from Gibco (Life Technol-
ogies, Illkirch, France). 3  105 cells were transfected in 6-well plates
using cationic lipid 2-{3-[bis-(3-amino-propyl)-amino]-propyla-
mino}-N-ditetradecyl carbamoyl methyl-acetamide or di-miristyl
aminopropyl aminopropyl (DMAPAP)65 in combination with
DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, Avanti Po-
lar Lipids). After 24 hr, the transfection mixture was replaced with64 Molecular Therapy: Nucleic Acids Vol. 11 June 2018fresh medium. One day later, various numbers of cells (from 2,000
to 30,000 per well, depending on the transfection conditions) were
transferred to selective medium supplemented with Geneticin
(G-418, 800 mg/mL, InvivoGen, Toulouse, France). Neomycin-resis-
tant clones were enumerated 11 days later, after staining with crystal
violet (0.1% dissolved in water). For each experiment, co-transfection
of cells with transposon and transposase plasmids was performed in
quadruplicates. When required, the amount of plasmid was adjusted
to the same final quantity using empty pFAR4 vector26 or pGL3-basic
(Promega, Madison, WI, USA). For the “colony-forming assays,”
transgenic rates correspond to transgene-expressing cells normalized
to the number of seeded cells.
Isolation and Cultivation of Primary Human RPE Cells
Human eyes from 13 donors (age, 69.4 ± 13.3 years; 7 males and 6
females) were obtained from the Aachen Cornea Bank of the Depart-
ment of Ophthalmology, University Hospital Rheinisch-Westfaeli-
sche Technische Hochschule (RWTH) Aachen. The eyes were
removed 29.1 ± 17.0 hr postmortem, after informed consent was ob-
tained, in accord with the Declaration of Helsinki. The procedures for
the collection and use of human samples were approved by the insti-
tutional ethics committee. For RPE cell isolation, the anterior segment
was removed by a circumferential cut approximately 3 mm posterior
to the limbus. After careful removal of the vitreous and the retina, the
posterior eyecup was filled with 1 mL DMEM/Ham’s F-12 (Bio-
chrom, Berlin, Germany) supplemented with 10% fetal bovine serum
(FBS; PAA Laboratories, Pasching, Austria), 80 U/mL penicillin and
80 mg/mL streptomycin (Lonza, Basel, Switzerland), and 2.5 mg/mL
amphotericin B (Sigma-Aldrich, Taufkirchen, Germany). The cells
were harvested by gently brushing the retinal pigment epithelium
with a fire-polished glass spatula. The procedure was repeated once.
After the eyecup was rinsed with 1 mL DMEM/Ham’s F-12 supple-
mented with 10% FBS, 80 U/mL penicillin, 80 mg/mL streptomycin,
and 2.5 mg/mL amphotericin B, the cell mixture was plated into 3
wells of a 24-well tissue culture plate. Cultures were maintained at
37C in a humidified atmosphere of 95% air and 5%CO2 until conflu-
ence was reached. The cell culture medium was changed twice a week.
Electroporation of Primary Human RPE Cells and Cultivation of
the Transfected Cells
Transfections were performed with the Neon transfection system us-
ing the 10 mL kit (Thermo Fisher Scientific, Waltham, MA) according
to the manufacturer’s protocol. The electroporation parameters were
as follows: 2 pulses, 1,100 V (pulse voltage), and 20 ms (pulse width).
1  105 or 1  104 cells in 11 mL resuspension buffer R (Thermo
Fisher Scientific) were combined with 2 mL of purified plasmid
mixture containing 30 ng of pFAR4-CMV-SB100X transposase
plasmid and either 470 ng of pT2-CAGGS-Venus, 470 ng of
pT2/BH-CMV-PEDF-BGH, 324 ng of pFAR4-ITRs-CAGGS-Venus,
or 313 ng of pFAR4-ITRs-CMV-PEDF-BGH, aiming at transfecting
cells with equimolar amount of Venus and PEDF transgenes. Empty
pFAR4 vector26 was used to reach the final plasmid amount of
500 ng. For analysis of Venus transgene expression, each experiment
comprised 2 transfection controls with electrical field application
www.moleculartherapy.orgwithout plasmid DNA and 2 transfections with electrical field appli-
cation and plasmid DNA for each of the pT2 and the pFAR4 vector.
For analysis of PEDF transgene expression, each experiment
comprised 4 transfection controls without electrical field application
and without plasmid DNA, 6 transfection controls with electrical field
application without plasmid DNA, and 10 transfections with electri-
cal field application and plasmid DNA for each of the pT2 and the
pFAR4 vector. Transfected cells were transferred into 24-well tissue
culture plates (for 1  105 cells) or 48-well tissue culture plates (for
1  104 cells) containing 1.0 mL or 0.5 mL of DMEM/Ham’s F-12
supplemented with 10% FBS without antibiotics or antimycotics.
Penicillin (80 U/mL), streptomycin (80 mg/mL), and amphotericin
B (2.5 mg/mL) were added with the first medium exchange 3 days after
electroporation. Cell cultures were either used after 2 or 3 weeks for
further analyses or maintained for analysis of long-term PEDF
expression and secretion.
SDS-PAGE and Western Blot Analysis
For SDS-PAGE, 15 mL of culture supernatant was mixed with an
equal volume of 2 SDS sample buffer66 and heated for 5 min at
95C. Proteins were separated on a 10% SDS-polyacrylamide gel
and transferred onto a 0.45-mm pore size nitrocellulose membrane
(Whatman International, Maidstone, UK) using the semi-dry transfer
system (Bio-Rad, Hercules, CA), followed by Ponceau S staining to
confirm the transfer. SDS-polyacrylamide gels that served as a loading
control were stained with GelCode blue stain reagent (Thermo Fisher
Scientific) according to the recommendations of the manufacturer.
For the detection of total (endogenous + recombinant) PEDF, blots
were blocked with 3% BSA/Tris-buffered saline (TBS) for 2 hr at
room temperature, incubated for 1 hr at room temperature and over-
night at 4C with anti-PEDF antibodies (rabbit polyclonal, 1:4,000
diluted in 3% BSA/TBS; BioProducts MD, Middletown, MD),
followed by incubation for 1 hr at room temperature with horseradish
peroxidase-conjugated anti-rabbit antibodies (goat polyclonal,
1:2,000 diluted in 10% milk powder/TBS; Abcam, Cambridge, UK).
Protein bands were visualized by chemiluminescence using the
LAS-3000 imaging system (FujiFilm, Tokyo, Japan) and evaluated
by the open source image processing program ImageJ (W.S. Rasband,
NIH, Bethesda, MD, USA; https://imagej.nih.gov/ij/; 1997–2014).
ELISA-Based Quantification of Total PEDF Secretion
Total PEDF secretion was analyzed in culture supernatants of control
and PEDF-transfected cells 3 weeks after transfection. Cells were
incubated for 24 hr in 0.5 mL of culture medium, from which
PEDF was quantified using the ELISAquant kit (BioProducts MD) ac-
cording to the manufacturer’s protocol and correlated with cell num-
ber. Cells were counted using the CASY Cell Counter Model TT
(Roche Diagnostics, Mannheim, Germany) after being trypsinized
with 0.05% trypsin-0.02% EDTA (PAA Laboratories).
Flow Cytometry
Trypsinized HeLa cells were fixed for 5 min in 1% formaldehyde
diluted in PBS and subsequently washed twice in PBS. Fluorescence
was quantified using a flow cytometer (Guava easyCyte, Merck Milli-pore). Fluorescent cells were sorted using either the ARIAIII or
FACSJAZZ cell sorters (BD Biosciences, Le Pont de Claix, France).
RPE cell monolayers were trypsinized with 0.05% trypsin-0.02%
EDTA (PAA Laboratories), washed three times in PBS, suspended
in 200 mL PBS, and analyzed using a FACSCalibur (Becton Dickinson,
Heidelberg, Germany).
Quantification of Transposon Insertions
Individual NeoR clones obtained after three independent transfec-
tions were selected in Geneticin-containing medium for 11 days
and passaged, on average, 7 times. Genomic DNA was prepared us-
ing the DNeasy blood and tissue kit (QIAGEN, Courtaboeuf,
France) according to the manufacturer’s instructions. NeoR gene
copy number was determined by qPCR in 384-well plates, each
well containing 20 ng of genomic DNA in a final volume of
10 mL, using the TaqMan Gene Expression Master Mix and
TaqMan Copy Number Assay made to order (MTO) kits for
neomycin resistance gene amplification (Applied Biosystems, Life
Technologies, Courtaboeuf, France). Results were normalized by
amplifying the RPPH1 gene, which is present as a single copy in
the human genome,67 using the TaqMan Copy Number Reference
Assay Human RNase P kit (Applied Biosystems). Primers and
probes of undisclosed sequences are provided with the kits. Fluores-
cence measurements were carried out using an ABIPRISM-7900HT
sequence detection system (Applied Biosystems) using the following
conditions: 50C for 2 min, 95C for 10 min, followed by 40 cycles
(95C for 15 s and 60C for 60 s). Melting curve analysis confirmed
the amplification specificity of each primer pair. Data were pro-
cessed with the ABI-PRISM-7900HT SDS software.
Reverse Transcription and qPCR
Total RNA was isolated using the RNeasy Mini Kit together with the
RNase-free DNase set (QIAGEN, Hilden, Germany) according to the
manufacturer’s protocol. Reverse transcription was carried out on
0.1 mg total RNA using a reverse transcription system (Promega,
Madison, WI). Real-time qPCR reactions were performed on a
LightCycler 1.2 instrument using the LightCycler FastStart DNA
Master SYBR Green I kit (Roche, Mannheim, Germany) according
to the manufacturer’s recommendations. The cDNA samples were
run in duplicate using the following primers for detection of the
endogenous PEDF gene plus the PEDF gene encoded by the pT2
and the pFAR4 plasmids: GAPDH as the internal control gene (for-
ward [F], 50-ATC CCA TCA CCA TCT TCC AG-30; reverse [R],
50-ATG AGT CCT TCC ACG ATA CC-30), endogenous PEDF
(F, 50-GCT GGC TTT GAG TGG AAC GA-30; R, 50-GTG TCC
TGT GGA ATC TGC TG-30), and endogenous plus recombinant
PEDF (F, 50-CCT GCA GGA GAT GAA GCT GCA-30; R, 50-TCC
ACC TGA GTC AGC TTG ATG-30). Reactions were performed
with diluted cDNA corresponding to 2 ng of initially used total
RNA and a primer concentration of 0.25 mM. Thermal cycler condi-
tions were as follows: initial denaturation at 95C for 10 min, followed
by 50 cycles with denaturation at 95C for 10 s, annealing at 60C for
8 s, and elongation at 72C for 15 s. Melting curve analysis confirmed
the amplification specificity of each primer pair. Data were processedMolecular Therapy: Nucleic Acids Vol. 11 June 2018 65
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CT (2DDCT) method, which describes relative gene expression.68
Statistical Analysis
Statistical analyses were performed using the tests indicated in the
figure legends and GraphPad Prism software version 5.04 (GraphPad,
La Jolla, CA).
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Supplemental Material 
Table S1. Western blot-based quantification of long-term PEDF secretion by primary human RPE cells 
transfected with SB100X and either pT2-PEDF or pFAR4-PEDF. Each analysis included 2 or 4 control 
transfections without the addition of plasmid DNA and 2 transfections using 30 ng of pFAR4-CMV SB100X SV40 
transposase and either 470 ng of pT2-ITRs CMV PEDF BGH or 313 ng of pFAR4-ITRs CMV PEDF BGH + 157 
ng of pFAR4/empty plasmid DNA. Culture supernatants were analyzed for total PEDF secretion at the times 
indicated. Western blot signal intensities obtained with pT2-PEDF transfected and pFAR4-PEDF transfected cells 
were normalized to the signal intensities detected with cells electroporated without plasmid DNA. Statistical 
analysis using one-way ANOVA with Tukey post test showed a significant difference (P£0.05) between non-
transfected and pFAR4-PEDF transfected cells. PEDF secretion of pT2-PEDF transfected cells compared to 
pFAR4-PEDF transfected cells was statistically different (P£0.01) for the first 103 days. 
 
 Time Number of Signal Intensities Statistics Tukey Post Test 
 [Days] [Donor 
Isolates] 
[Samples] [Mean  
± SD] 
[Range] One-way 
ANOVA 
Control vs. 
pT2-PEDF 
pFAR4-PEDF 
pT2-PEDF vs. 
pFAR4-PEDF 
Control 
pT2-PEDF 
pFAR4-PEDF 
51  
± 9 
10 38 
14 
20 
1.00 ± 0.22 
2.16 ± 1.84 
4.74 ± 4.38 
0.64-1.63 
0.21-5.48 
0.65-17.5 
 
 
****P<0.0001 
 
Not significant 
***P£0.001 
 
 
**P£0.01 
Control 
pT2-PEDF 
pFAR4-PEDF 
103  
± 7 
8 30 
10 
16 
1.00 ± 0.31 
1.89 ± 1.16 
5.24 ± 4.99 
0.45-1.66 
0.54-4.15 
0.86-16.9 
 
 
****P<0.0001 
 
Not significant 
***P£0.001 
 
 
**P£0.01 
Control 
pT2-PEDF 
pFAR4-PEDF 
150  
± 4 
6 22 
12 
12 
1.00 ± 0.36 
2.21 ± 1.92 
6.26 ± 8.08 
0.37-1.63 
0.61-6.73 
0.92-27.7 
 
 
**P=0.0044 
 
Not significant 
**P£0.01 
 
 
Not significant 
Control 
pT2-PEDF 
pFAR4-PEDF 
197  
± 3 
5 18 
10 
10 
1.00 ± 0.39 
1.16 ± 0.53 
5.75 ± 9.19 
0.46-1.91 
0.49-2.43 
1.01-30.8 
 
 
*P=0.0345 
 
Not significant 
*P£0.05 
 
 
Not significant 
Control 
pT2-PEDF 
pFAR4-PEDF 
240  
± 15 
5 22 
12 
12 
1.00 ± 0.35 
1.56 ± 1.33 
6.73 ± 11.4 
0.51-1.97 
0.53-4.25 
0.65-41.4 
 
 
*P=0.0276 
 
Not significant 
*P£0.05 
 
 
Not significant 
 
